<Back to Therapeutic Areas

<Back to Menu

Immunology

IME/CME for HCPs

GSK identifies and funds innovative, high-quality, independent third-party educational initiatives that are designed to close healthcare professional (HCP) educational, quality, and performance gaps to improve patient health and quality of life. GSK provides financial support for independent medical education (IME) for HCPs, including certified continuing medical education (CME, CE), with a grant.

Educational providers are fully compliant with the ACCME (and other nationally recognized accrediting body) standards for commercial support and design and deliver all activities (including content, faculty, speakers, and educational materials) independent from GSK control, influence, and involvement.

These initiatives offer opportunities for continual learning regarding educational topics and are free for learners to access. For more information about any of these initiatives, please click the link to be directed to the educational provider's website. All questions about these activities should be directed to the educational provider listed for each activity, not to GSK, as these are not GSK initiatives.


More Options and More to Come Update on the Management of LN

Expiration Date: December 31, 2022

Educational Provider: American Society of Nephrology


Diagnosis and Optimal Treatment for SLE and Lupus Nephritis

Expiration Date: July 14, 2023

Educational Provider: National Kidney Foundation


SLE Curbside Consults Tackling Challenging Cases

Expiration Date: March 30, 2023

Educational Provider: Vindico Medical Education, LLC


SLE Treat to Target and Beyond

Expiration Date: March 30, 2023

Educational Provider: Vindico Medical Education, LLC


SLE Game On Clinical Advances in SLE

Expiration Date: February 27, 2023

Educational Provider: Vindico Medical Education, LLC


Assessing Managing Engaging Patients in SLE and LN

Expiration Date: December 4, 2023

Educational Provider: Medical Learning Institute, Inc


Lupus and Lupus Nephritis Improving Outcomes

Expiration Date: June 14, 2023

Educational Provider: Clinical Care Options


Lupus Nephritis What Are the New Approaches in Therapy

Expiration Date: December 30, 2022

Educational Provider: Medscape LLC


Treating SLE to Minimize Organ Damage and Optimize Outcomes

Expiration Date: May 9, 2023

Educational Provider: Postgraduate Institute for Medicine


GSK Immunology will have a presence at the meetings listed below. Please visit us at our medical affairs booths to view our medical information.

Meet Us

Southwest Nephrology Conference | Mar 17-18, 2022 | Scottsdale, AZ

NKF | Apr 6-10, 2022 | Boston, MA

CCR East | May 12-15, 2022 | Destin, FL

CCR West | Oct 20-23, 2022 | San Diego, CA

ASN | Nov 1-6, 2022 | Orlando, FL

ACR | Nov 11-15, 2022 | Philadelphia, PA

View information about our marketed products Benlysta and Nucala including prescribing information, material safety data sheets and environmental risks assessments pertaining to these products.

View educational materials from GSK Medical on selected disease states.

Systemic Lupus Erythematosus(SLE) / Lupus Nephritis(LN)

Lupus Nephritis : The Case for Early Recognition and Management (46:01)

Understanding Complications, Monitoring and Management of Patients with SLE (24:39)

Hypereosinophilic Syndrome (HES)

HES Mechanism of Disease (6:24)

Elevated Blood Eosinophils: What to Do Next Video (35:38)

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

On-Demand Webinars

Presented by: Dr. Michael E. Wechsler, MD, MMSc

EGPA: Pathogenesis, Diagnosis, and Management (28:06)

EGPA Mechanism of Disease (3:54)

View our ongoing, innovative research with autoimmune diseases.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Phase II Phase III Phase IV

SABLE: Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry

NCT01729455

Belimumab Pregnancy Registry

NCT01532310

BLISS-BELIEVE: Belimumab Subcutaneous in Combination with Rituximab in Adult SLE

NCT03312907
RHEUMATOID ARTHRITIS (RA) Phase II Phase III Phase IV

ContRAst-1: Otilimab vs Placebo and Tofacitinib in Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Methotrexate

NCT03980483

ContRAst-2: Otilimab vs Placebo and Tofacitinib in Moderately to Severely Active RA who have Inadequate Response to Conventional Synthetic DMARDs

NCT03970837

ContRAst-3: Otilimab vs Placebo and Sarilumab in Moderately to Severely Active RA with Inadequate Response to Biologic DMARDs and/or JAKI

NCT04134728

Mechanistic Study of Otilimab Plus Methotrexate in Active Rheumatoid Arthritis Despite Treatment With DMARDs

NCT02799472
(Phase IIa)

Otilimab Plus Methotrexate in Active Moderate-Severe Rheumatoid Arthritis

NCT02504671
(Phase IIb)
EOSINOPHILIC GRANULOMATOSIS
WITH POLYANGIITIS (EGPA)
Phase II Phase III Phase IV

VCRC-VPPRN EGPA Registry (Observational Study)*

NCT00315380 (Observational)

Access important product resources such as the Belimumab Vial Calculator and Blood Eosinophil Unit Conversion Calculator and search for scientific literature.

GSK Immunology Medical Team attends several key medical congresses. You can access presentations, posters, and symposia material below.

European Alliance of Associations for Rheumatology (EULAR)

June 1-4, 2022 | Hybrid | Copenhagen, Denmark

American Society of Nephrology (ASN) Kidney Week

November 4-7, 2021 | Virtual

American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) Annual Meeting

November 3-9, 2021 | Virtual

College of Clinical Rheumatology

August 12-15, 2021 | Destin, FL | Virtual